Potentiated antitumor activity of poly-γ-glutamic acid combined with anti PD-L1 blockade on murine models of colorectal cancer

被引：0
|
作者：
Jang, Jae-Pyung
Yoo, Chan-Hee
Hahm, Kyung-Soo
Lee, Do Young
Park, Young-Chul
Choi, Jae Chul
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4044
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4044
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
    Janice M. Mehnert
    Andrea Varga
    Marcia S. Brose
    Rahul R. Aggarwal
    Chia-Chi Lin
    Amy Prawira
    Filippo de Braud
    Kenji Tamura
    Toshihiko Doi
    Sarina A. Piha-Paul
    Jill Gilbert
    Sanatan Saraf
    Pradeep Thanigaimani
    Jonathan D. Cheng
    Bhumsuk Keam
    BMC Cancer, 19
  • [32] Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer
    Gu, Zili
    Da Silva, Candido G.
    Hao, Yang
    Schomann, Timo
    Camps, Marcel G. M.
    van der Maaden, K.
    Liu, Qi
    Ossendorp, Ferry
    Cruz, Luis J.
    JOURNAL OF CONTROLLED RELEASE, 2023, 353 : 490 - 506
  • [33] A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity
    Shi, Wenqiang
    Lv, Liangyin
    Liu, Nan
    Wang, Hui
    Wang, Yang
    Zhu, Wen
    Liu, Zexin
    Zhu, Jianwei
    Lu, Huili
    MOLECULAR THERAPY, 2023, 31 (01) : 66 - 77
  • [34] PD-L1 immune checkpoint blockade in genetically engineered mouse models of prostate cancer
    Shimizu, Nobutaka
    De Velasco, Marco A.
    Kura, Yurie
    Sakai, Kazuko
    Sugimoto, Kouichi
    Nozawa, Masahiro
    Yoshimura, Kazuhiro
    Yoshikawa, Kazuhiro
    Nishio, Kazuto
    Uemura, Hirotsugu
    CANCER SCIENCE, 2018, 109 : 292 - 292
  • [35] Combined treatment with PD-L1 blockade and a TLR7/8 agonist dramatically enhances antitumor immunity
    Nishii, Naoto
    Kondo, Yuta
    Li, Lixin
    Lau, Walter
    Harada, Hiroyuki
    Azuma, Miyuki
    CANCER RESEARCH, 2016, 76
  • [36] FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
    Lakins, Matthew A.
    Koers, Alexander
    Giambalvo, Raffaella
    Munoz-Olaya, Jose
    Hughes, Robert
    Goodman, Emma
    Marshall, Sylwia
    Wollerton, Francisca
    Batey, Sarah
    Gliddon, Daniel
    Tuna, Mihriban
    Brewis, Neil
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 4154 - 4167
  • [37] USP18 Is Associated with PD-L1 Antitumor Immunity and Improved Prognosis in Colorectal Cancer
    Jifu, Cili
    Lu, Linxia
    Ding, Jiaxin
    Lv, Mengjun
    Xia, Jun
    Wang, Jingtao
    Wang, Peijun
    BIOMOLECULES, 2024, 14 (09)
  • [38] Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity
    He, Ningning
    Huang, Hao
    Wu, Shaoxian
    Ji, Weipeng
    Tai, Yicheng
    Gao, Ruicheng
    Liu, Yingting
    Liu, Yungang
    Chen, Lujun
    Zhu, Dawei
    Zheng, Xiao
    Jiang, Jingting
    CANCER SCIENCE, 2024, 115 (07) : 2196 - 2208
  • [39] IL-6 and PD-L1 Antibody Blockade Combination Therapy Limits Tumor Progression in Murine Models of Pancreatic Cancer
    Mace, T.
    Shakya, R.
    Pitarresi, J. R.
    Swanson, B.
    McQuinn, C.
    Loftus, S.
    Yu, L.
    Young, G.
    Zhong, X.
    Zimmers, T.
    Ostrowski, M.
    Ludwig, T.
    Dillhoff, M.
    Schmidt, C.
    Conwell, D. L.
    Bekaii-Saab, T.
    Lesinski, G.
    PANCREAS, 2016, 45 (10) : 1521 - 1522
  • [40] IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
    Mace, Thomas A.
    Shakya, Reena
    Pitarresi, Jason R.
    Swanson, Benjamin
    McQuinn, Christopher W.
    Loftus, Shannon
    Nordquist, Emily
    Cruz-Monserrate, Zobeida
    Yu, Lianbo
    Young, Gregory
    Zhong, Xiaoling
    Zimmers, Teresa A.
    Ostrowski, Michael C.
    Ludwig, Thomas
    Bloomston, Mark
    Bekaii-Saab, Tanios
    Lesinski, Gregory B.
    GUT, 2018, 67 (02) : 320 - 332
12345